Page Title
Drug Development Pipeline
Hypertonic Saline
Status
To PatientsTherapeutic Approach
Mucociliary Clearance
Hypertonic saline as an inhaled therapy is believed to increase hydration of airway surface liquid in people with CF, thereby improving mucus clearance.
Status
A phase 3 study conducted in Australia showed beneficial effects of hypertonic saline on pulmonary health in people with CF ages 6 years and older. A phase 2 study of hypertonic saline in preschool children showed that using inhaled hypertonic saline twice a day resulted in less structural lung disease as measured by CT scan compared with inhaled normal saline.
Sponsor
The program was funded through the Cystic Fibrosis Foundation and facilitated by the Therapeutics Development Network.
CONTACT THE CLINICAL TRIAL NAVIGATOR
Get personalized assistance and answers to your clinical trial questions.
Learn MoreSign up for clinical trial alerts
Get email updates about clinical trials that matter to you.
Explore clinical trials
Be a part of the movement transforming the future of cystic fibrosis treatment.
Learn More